Pharyngitis Market
Pharyngitis Market Study by Beta Lactams, Macrolides, Cephalosporins, Fluoroquinolones, and Tetracycline Sold at Hospital Pharmacies, Retail Pharmacies & Drug Stores, and Online from 2024 to 2034
Analysis of Pharyngitis Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Pharyngitis Market Outlook (2024 to 2034)
High levels of exposure to smoking, pollution, dry air, and various other environmental irritants such as strong fumes, allergens, etc., are directly damaging the pharyngeal tissues, which is driving up demand for effective pharyngitis treatment options. This has led to the global pharyngitis market size reaching a value of US$ 1.45 billion in 2024 and expected to increase to US$ 2.08 billion by 2034, expanding at a CAGR of 3.7% from 2024 to 2034.
In recent years, effective medications, including NSAIDs (non-steroidal anti-inflammatory drugs), antibiotics, antivirals, etc. have been adopted for the management of disease symptoms or treatment of ailments, which is further contributing to pharyngitis market growth. In addition, the inflating application of throat sprays or lozenges, containing numbing agents, menthol and lozenges, to relieve pain and discomfort by soothing the irritated tissues, is further contributing to the expansion of the pharyngitis market size.
Growing popularity of photobiomodulation therapy is attributed to its use of low-level lasers or light-emitting diodes to stimulate cellular function among patients. This therapy is also used to promote throat healing, thus driving opportunities for global market players.
- Western Europe is projected to account for 17.6% share of the global market by 2034-end.
- Demand for pharyngitis treatment products in Japan is expected to increase at a CAGR of 1.3% from 2024 to 2034.
- Worldwide sales of beta-lactams are projected to increase at a CAGR of 3.7% and reach US$ 776.3 million by the end of 2034.
Growing preference for novel therapeutics, rising adoption of personalized medications, and increasing incidences of clinical trials are contributing to the demand for pharyngitis treatment solutions. Moreover, constant advancements in treatment methods and inclination to OTC (Over-the-counter) medicines are also estimated to positively influence pharyngitis market trends across regions in the coming 10 years.
| Report Attributes | Details |
|---|---|
| Pharyngitis Market Size (2024E) | US$ 1.45 Billion |
| Forecasted Market Value (2034F) | US$ 2.08 Billion |
| Global Market Growth Rate (2024 to 2034) | 3.7% CAGR |
| Market Share of Retail Pharmacies & Drug Stores (2034F) | 58.5% |
| South Korea Market Growth (2024 to 2034) | 4.4% CAGR |
| South Asia & Pacific Market Share (2034F) | 21.9% |
| Key Companies Profiled | Pfizer Inc.; Novartis AG; GlaxoSmithKline PLC; Zambon Group SpA.; BioStar Pharmaceuticals Inc. |
Don't Need a Global Report?
save 40%! on Country & Region specific reports
What’s Shaping the Market for Pharyngitis Treatment?
“Growing Demand for OTC Medicines”
An increase in the demand for OTC medications is encountered, which is projected to positively influence the demand for pharyngitis treatment options. There are various types of OTC pharyngitis medications, such as sprays, pain relievers, throat lozenges, multiple types of drugs, etc., readily available in convenience stores, hospitals, supermarkets, and online and retail pharmacies.
More patients are purchasing OTC products that too without any visit to a clinic or hospital or prescription, therefore making them more convenient for immediate symptom relief. The ability of OTC medications to offer relief for common symptoms, such as sore throat, discomfort, etc. is driving opportunities for players.
“Rising Preference for Novel Therapeutics”
In recent years, an increased demand for novel therapeutics has been encountered across regions. Present market available therapeutics and treatments are used widely, especially antibiotics. The constant involvement of manufacturers in novel therapeutics with better patient outcomes is estimated to result in minimal side effects to human beings. Therefore, a positive impact on market growth is encountered.
What Restraints are Limiting Demand Growth for Pharyngitis Treatment Options?
“Side Effects of Antibiotics and Availability of Alternative Treatment Options”
There are certain moderate side effects associated with the consumption of antibiotics used against pharyngitis. Some of these side effects are rashes, diarrhea, dizziness, and some other adverse effects encountered by patients consuming antibiotics.
Easy availability of alternative treatment is adversely impacting demand for pharyngitis treatment products. More pharyngitis patients are inclined to natural remedies, including ginger, honey, herbal products, including herbal tea, etc. to avoid the side effects of drugs.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
How Lucrative Will the Global Market Be for Startups?
“Offering Customized Pharyngitis Treatment Solutions”
Aspiring market players are expected to focus more on the development of medications according to clinical requirements as well as matching individual needs. These new entrants are anticipated to offer products with minimum side effects to help in rapid healing while causing minimal harm to the human body. Thus, these initiatives are estimated to help players secure a position for themselves while ensuring the utmost comfort to patients.
Country-wise Insights
With favorable reimbursement policies and advanced healthcare infrastructure, North America is anticipated to account for 35.9% share of the global market by the end of 2034.
Why is the United States a Highly Lucrative Market?
“Market Expansion Complemented by Presence of Well-established Healthcare Infrastructure”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 453.3 Million |
| Growth Rate (2024 to 2034) | 4% CAGR |
| Projected Value (2034F) | US$ 673.1 Million |
With the presence of well-established and advanced healthcare infrastructure, such as specialty clinics, hospitals, ENT clinics, and others, the United States is estimated to hold 86.8% share of the North American market by the end of 2034. These healthcare institutes offer better therapeutics and treatment facilities for quick relief from pharyngitis. Further, an increase in the cases of pharyngitis is set to generate demand for effective therapeutics, which contribute to improved patient outcomes. The availability of supportive healthcare insurance facilities and reimbursement policies is expected to positively impact demand for pharyngitis treatment services in the country.
Why is There an Increase in Demand for Pharyngitis Treatment Products in China?
“Growing Expenditure on R&D Activities to Offer Advanced Healthcare Facilities”
| Attribute | China |
|---|---|
| Market Value (2024E) | US$ 109.2 Million |
| Growth Rate (2024 to 2034) | 5.4% CAGR |
| Projected Value (2034F) | US$ 184.6 Million |
Increasing investments in advanced healthcare facilities in China is set to help the country account for 50.9% share of the market in East Asia by the end of 2034. Healthcare providers are now able to offer more efficient pharyngitis treatment solutions to patients to improve the issues and symptoms related to throat infections.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Category-wise Insights
Fact.MR, a market research and competitive intelligence provider, in its recently updated report, asserts that demand for pharyngitis treatment products through retail pharmacies and drug stores is projected to increase at a CAGR of 3.9% and reach a value of US$ 1.22 billion by the end of 2034. Issues related to sore throats are very common, therefore pharmacists assess particular symptoms as mentioned by patients. In addition, the introduction of novel products by pharmaceutical companies is projected to help respective patients get rapid relief from pain.
Which Drug Class is More Preferred in the This Market?
“Rising Use of Beta Lactams as Commonly Preferred Drug”
| Attribute | Beta Lactams |
|---|---|
| Segment Value (2024E) | US$ 540.8 Million |
| Growth Rate (2024 to 2034) | 3.7% CAGR |
| Projected Value (2034F) | US$ 776.3 Million |
Beta lactams are anticipated to hold 37.2% of the pharyngitis market share by the end of the assessment period in 2034. Beta lactams are set to emerge as one of the commonly preferred drug classes over other options. Penicillins and cephalosporins are included in beta-lactams. These drugs are used as effective solutions against numerous harmful organisms. Further, recent developments taking place for the production of broad-spectrum beta-lactam antibiotics, which are used actively against gram-negative organisms are increasing their use.
What Mode of Drug Delivery is Common for Pharyngitis Treatment?
“High Use of Oral Delivery Mode Due to Convenience and Cost-effectiveness”
| Attribute | Oral Delivery Mode |
|---|---|
| Segment Value (2024E) | US$ 619.8 Million |
| Growth Rate (2024 to 2034) | 3.6% CAGR |
| Projected Value (2034F) | US$ 879.7 Million |
The oral drug delivery mode is approximated to account for 42.2% share of the global market by the end of 2034. High patient compliance, convenience, and cost-effectiveness are key features of this oral drug delivery mode, which are attracting more patients.
Competitive Landscape
Increasing use of advanced healthcare technologies ensures more efficient facilities, which is further generating lucrative opportunities for providers of pharyngitis treatment solutions. Thus, the incorporation of various strategies, including mergers, maintaining product quality control, new product development, acquisitions, and supplying quality healthcare products, helps players to get a competitive edge.
Pfizer Inc., Novartis AG, GlaxoSmithKline PLC, Zambon Group SpA., and BioStar Pharmaceuticals Inc. are key players in the pharyngitis market.
Segmentation of Pharyngitis Market Research
-
By Drug Class :
- Beta Lactams
- Macrolides
- Cephalosporins
- Fluoroquinolones
- Tetracycline
- Reusable
-
By Mode of Delivery :
- Oral
- Intravenous
- Intramuscular
-
By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
-
By Region :
- North America
- Europe
- East Asia
- Latin America
- Middle East & Africa
- South Asia & Oceania
Table of Content
- 1. Global Economic Outlook
- 2. Global Market - Executive Summary
- 3. Global Market Overview
- 4. Global Market Analysis and Forecast 2018 to 2034
- 4.1. Global Market Size and Forecast By Drug Class, 2018 to 2034
- 4.1.1. Beta Lactams
- 4.1.2. Macrolides
- 4.1.3. Cephalosporins
- 4.1.4. Fluoroquinolones
- 4.1.5. Tetracycline
- 4.1.6. Other Products
- 4.2. Global Market Size and Forecast By Distribution Channel, 2018 to 2034
- 4.2.1. Hospital Pharmacies
- 4.2.2. Retail Pharmacies and Drug Stores
- 4.2.3. Online Pharmacies
- 4.3. Global Market Size and Forecast By Mode of Delivery, 2018 to 2034
- 4.3.1. Oral
- 4.3.2. Intravenous
- 4.3.3. Intramuscular
- 4.3.4. Other Mode of Delivery
- 4.1. Global Market Size and Forecast By Drug Class, 2018 to 2034
- 5. North America Market Size and Forecast, 2018 to 2034
- 6. Latin America Market Size and Forecast, 2018 to 2034
- 7. Europe Market Size and Forecast, 2018 to 2034
- 8. Japan Market Size and Forecast, 2018 to 2034
- 9. APEJ Market Size and Forecast, 2018 to 2034
- 10. MEA Market Size and Forecast, 2018 to 2034
- 11. Global Market Company Share, Competition Landscape and Company Profiles
- 11.1. GlaxoSmithKline PLC
- 11.2. Pfizer Inc.
- 11.3. Teva Pharmaceutical Industries Limited
- 11.4. Merck KGaA
- 11.5. Sanofi
- 11.6. Abbott Laboratories Inc.
- 11.7. Novartis AG
- 11.8. Zambon Group SpA
- 11.9. BioStar Pharmaceuticals, Inc.
- 12. Research Methodology
- 13. Secondary and Primary Sources
- 14. Assumptions and Acronyms
- 15. Disclaimer
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
TABLE 01: Global Market Value (US$ Mn), 2018 to 2023
TABLE 02: Global Market Value (US$ Mn), 2024 to 2034
TABLE 03: Global Market Value (US$ Mn) and Y-o-Y, 2024 to 2034
TABLE 04: Global Beta Lactams Segment Value (US$ Mn), By Region 2018 to 2023
TABLE 05: Global Beta Lactams Segment Value (US$ Mn), By Region 2024 to 2034
TABLE 06: Global Beta Lactams Segment Market Share, By Region 2018 to 2023
TABLE 07: Global Beta Lactams Segment Market Share, By Region 2024 to 2034
TABLE 08: Global Beta Lactams Segment Y-o-Y, By Region 2024 to 2034
TABLE 09: Global Macrolides Segment Value (US$ Mn), By Region 2018 to 2023
TABLE 10: Global Macrolides Segment Value (US$ Mn), By Region 2024 to 2034
TABLE 11: Global Macrolides Segment Market Share, By Region 2018 to 2023
TABLE 12: Global Macrolides Segment Market Share, By Region 2024 to 2034
TABLE 13: Global Macrolides Segment Y-o-Y, By Region 2024 to 2034
TABLE 14: Global Cephalosporins Segment Value (US$ Mn), By Region 2018 to 2023
TABLE 15: Global Cephalosporins Segment Value (US$ Mn), By Region 2024 to 2034
TABLE 16: Global Cephalosporins Segment Market Share, By Region 2018 to 2023
TABLE 17: Global Cephalosporins Segment Market Share, By Region 2024 to 2034
TABLE 18: Global Cephalosporins Segment Y-o-Y, By Region 2024 to 2034
TABLE 19: Global Fluoroquinolones Segment Value (US$ Mn), By Region 2018 to 2023
TABLE 20: Global Fluoroquinolones Segment Value (US$ Mn), By Region 2024 to 2034
TABLE 21: Global Fluoroquinolones Segment Market Share, By Region 2018 to 2023
TABLE 22: Global Fluoroquinolones Segment Market Share, By Region 2024 to 2034
TABLE 23: Global Fluoroquinolones Segment Y-o-Y, By Region 2024 to 2034
TABLE 24: Global Tetracycline Segment Value (US$ Mn), By Region 2018 to 2023
TABLE 25: Global Tetracycline Segment Value (US$ Mn), By Region 2024 to 2034
TABLE 26: Global Tetracycline Segment Market Share, By Region 2018 to 2023
TABLE 27: Global Tetracycline Segment Market Share, By Region 2024 to 2034
TABLE 28: Global Tetracycline Segment Y-o-Y, By Region 2024 to 2034
TABLE 29: Global Other Products Segment Value (US$ Mn), By Region 2018 to 2023
TABLE 30: Global Other Products Segment Value (US$ Mn), By Region 2024 to 2034
TABLE 31: Global Other Products Segment Market Share, By Region 2018 to 2023
TABLE 32: Global Other Products Segment Market Share, By Region 2024 to 2034
TABLE 33: Global Other Products Segment Y-o-Y, By Region 2024 to 2034
TABLE 34: Global Hospital Pharmacies Segment Value (US$ Mn), By Region 2018 to 2023
TABLE 35: Global Hospital Pharmacies Segment Value (US$ Mn), By Region 2024 to 2034
TABLE 36: Global Hospital Pharmacies Segment Market Share, By Region 2018 to 2023
TABLE 37: Global Hospital Pharmacies Segment Market Share, By Region 2024 to 2034
TABLE 38: Global Hospital Pharmacies Segment Y-o-Y, By Region 2024 to 2034
TABLE 39: Global Retail Pharmacies and Drug Stores Segment Value (US$ Mn), By Region 2018 to 2023
TABLE 40: Global Retail Pharmacies and Drug Stores Segment Value (US$ Mn), By Region 2024 to 2034
TABLE 41: Global Retail Pharmacies and Drug Stores Segment Market Share, By Region 2018 to 2023
TABLE 42: Global Retail Pharmacies and Drug Stores Segment Market Share, By Region 2024 to 2034
TABLE 43: Global Retail Pharmacies and Drug Stores Segment Y-o-Y, By Region 2024 to 2034
TABLE 44: Global Online Pharmacies Segment Value (US$ Mn), By Region 2018 to 2023
TABLE 45: Global Online Pharmacies Segment Value (US$ Mn), By Region 2024 to 2034
TABLE 46: Global Online Pharmacies Segment Market Share, By Region 2018 to 2023
TABLE 47: Global Online Pharmacies Segment Market Share, By Region 2024 to 2034
TABLE 48: Global Online Pharmacies Segment Y-o-Y, By Region 2024 to 2034
TABLE 49: Global Oral Segment Value (US$ Mn), By Region 2018 to 2023
TABLE 50: Global Oral Segment Value (US$ Mn), By Region 2024 to 2034
TABLE 51: Global Oral Segment Market Share, By Region 2018 to 2023
TABLE 52: Global Oral Segment Market Share, By Region 2024 to 2034
TABLE 53: Global Oral Segment Y-o-Y, By Region 2024 to 2034
TABLE 54: Global Intravenous Segment Value (US$ Mn), By Region 2018 to 2023
TABLE 55: Global Intravenous Segment Value (US$ Mn), By Region 2024 to 2034
TABLE 56: Global Intravenous Segment Market Share, By Region 2018 to 2023
TABLE 57: Global Intravenous Segment Market Share, By Region 2024 to 2034
TABLE 58: Global Intravenous Segment Y-o-Y, By Region 2024 to 2034
TABLE 59: Global Intramuscular Segment Value (US$ Mn), By Region 2018 to 2023
TABLE 60: Global Intramuscular Segment Value (US$ Mn), By Region 2024 to 2034
TABLE 61: Global Intramuscular Segment Market Share, By Region 2018 to 2023
TABLE 62: Global Intramuscular Segment Market Share, By Region 2024 to 2034
TABLE 63: Global Intramuscular Segment Y-o-Y, By Region 2024 to 2034
TABLE 64: Global Other Mode of Delivery Segment Value (US$ Mn), By Region 2018 to 2023
TABLE 65: Global Other Mode of Delivery Segment Value (US$ Mn), By Region 2024 to 2034
TABLE 66: Global Other Mode of Delivery Segment Market Share, By Region 2018 to 2023
TABLE 67: Global Other Mode of Delivery Segment Market Share, By Region 2024 to 2034
TABLE 68: Global Other Mode of Delivery Segment Y-o-Y, By Region 2024 to 2034
TABLE 69: North America Current Expenditure on Health, (% of GDP), by Country, 2018 to 2023
TABLE 70: North America Per Capita Health Expenditure (US$ PPP), by Country, 2018 to 2023
TABLE 71: North America Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2018 to 2023
TABLE 72: North America Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2018 to 2023
TABLE 73: North America Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2018 to 2023
TABLE 74: North America Market Value (US$ Mn), By Country 2018 to 2023
TABLE 75: North America Market Value (US$ Mn), By Country 2024 to 2034
TABLE 76: North America Market Value (US$ Mn), By Drug Class 2018 to 2023
TABLE 77: North America Market Value (US$ Mn), By Drug Class 2024 to 2034
TABLE 78: North America Market Value (US$ Mn), By Distribution Channel 2018 to 2023
TABLE 79: North America Market Value (US$ Mn), By Distribution Channel 2024 to 2034
TABLE 80: North America Market Value (US$ Mn), By Mode of Delivery 2018 to 2023
TABLE 81: North America Market Value (US$ Mn), By Mode of Delivery 2024 to 2034
TABLE 82: Latin America Current Expenditure on Health, (% of GDP), by Country, 2018 to 2023
TABLE 83: Latin America Per Capita Health Expenditure (US$ PPP), by Country, 2018 to 2023
TABLE 84: Latin America Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2018 to 2023
TABLE 85: Latin America Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2018 to 2023
TABLE 86: Latin America Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2018 to 2023
TABLE 87: Latin America Market Value (US$ Mn), By Country 2018 to 2023
TABLE 88: Latin America Market Value (US$ Mn), By Country 2024 to 2034
TABLE 89: Latin America Market Value (US$ Mn), By Drug Class 2018 to 2023
TABLE 90: Latin America Market Value (US$ Mn), By Drug Class 2024 to 2034
TABLE 91: Latin America Market Value (US$ Mn), By Distribution Channel 2018 to 2023
TABLE 92: Latin America Market Value (US$ Mn), By Distribution Channel 2024 to 2034
TABLE 93: Latin America Market Value (US$ Mn), By Mode of Delivery 2018 to 2023
TABLE 94: Latin America Market Value (US$ Mn), By Mode of Delivery 2024 to 2034
TABLE 95: Europe Current Expenditure on Health, (% of GDP), by Country, 2018 to 2023
TABLE 96: Europe Per Capita Health Expenditure (US$ PPP), by Country, 2018 to 2023
TABLE 97: Europe Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2018 to 2023
TABLE 98: Europe Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2018 to 2023
TABLE 99: Europe Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2018 to 2023
TABLE 100: Europe Market Value (US$ Mn), By Country 2018 to 2023
TABLE 101: Europe Market Value (US$ Mn), By Country 2024 to 2034
TABLE 102: Europe Market Value (US$ Mn), By Drug Class 2018 to 2023
TABLE 103: Europe Market Value (US$ Mn), By Drug Class 2024 to 2034
TABLE 104: Europe Market Value (US$ Mn), By Distribution Channel 2018 to 2023
TABLE 105: Europe Market Value (US$ Mn), By Distribution Channel 2024 to 2034
TABLE 106: Europe Market Value (US$ Mn), By Mode of Delivery 2018 to 2023
TABLE 107: Europe Market Value (US$ Mn), By Mode of Delivery 2024 to 2034
TABLE 108: Japan Current Expenditure on Health, (% of GDP), by Country, 2018 to 2023
TABLE 109: Japan Per Capita Health Expenditure (US$ PPP), by Country, 2018 to 2023
TABLE 110: Japan Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2018 to 2023
TABLE 111: Japan Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2018 to 2023
TABLE 112: Japan Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2018 to 2023
TABLE 113: Japan Market Value (US$ Mn), By Country 2018 to 2023
TABLE 114: Japan Market Value (US$ Mn), By Country 2024 to 2034
TABLE 115: Japan Market Value (US$ Mn), By Drug Class 2018 to 2023
TABLE 116: Japan Market Value (US$ Mn), By Drug Class 2024 to 2034
TABLE 117: Japan Market Value (US$ Mn), By Distribution Channel 2018 to 2023
TABLE 118: Japan Market Value (US$ Mn), By Distribution Channel 2024 to 2034
TABLE 119: Japan Market Value (US$ Mn), By Mode of Delivery 2018 to 2023
TABLE 120: Japan Market Value (US$ Mn), By Mode of Delivery 2024 to 2034
TABLE 121: APEJ Current Expenditure on Health, (% of GDP), by Country, 2018 to 2023
TABLE 122: APEJ Per Capita Health Expenditure (US$ PPP), by Country, 2018 to 2023
TABLE 123: APEJ Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2018 to 2023
TABLE 124: APEJ Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2018 to 2023
TABLE 125: APEJ Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2018 to 2023
TABLE 126: APEJ Market Value (US$ Mn), By Country 2018 to 2023
TABLE 127: APEJ Market Value (US$ Mn), By Country 2024 to 2034
TABLE 128: APEJ Market Value (US$ Mn), By Drug Class 2018 to 2023
TABLE 129: APEJ Market Value (US$ Mn), By Drug Class 2024 to 2034
TABLE 130: APEJ Market Value (US$ Mn), By Distribution Channel 2018 to 2023
TABLE 131: APEJ Market Value (US$ Mn), By Distribution Channel 2024 to 2034
TABLE 132: APEJ Market Value (US$ Mn), By Mode of Delivery 2018 to 2023
TABLE 133: APEJ Market Value (US$ Mn), By Mode of Delivery 2024 to 2034
TABLE 134: MEA Current Expenditure on Health, (% of GDP), by Country, 2018 to 2023
TABLE 135: MEA Per Capita Health Expenditure (US$ PPP), by Country, 2018 to 2023
TABLE 136: MEA Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2018 to 2023
TABLE 137: MEA Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2018 to 2023
TABLE 138: MEA Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2018 to 2023
TABLE 139: MEA Market Value (US$ Mn), By Country 2018 to 2023
TABLE 140: MEA Market Value (US$ Mn), By Country 2024 to 2034
TABLE 141: MEA Market Value (US$ Mn), By Drug Class 2018 to 2023
TABLE 142: MEA Market Value (US$ Mn), By Drug Class 2024 to 2034
TABLE 143: MEA Market Value (US$ Mn), By Distribution Channel 2018 to 2023
TABLE 144: MEA Market Value (US$ Mn), By Distribution Channel 2024 to 2034
TABLE 145: MEA Market Value (US$ Mn), By Mode of Delivery 2018 to 2023
TABLE 146: MEA Market Value (US$ Mn), By Mode of Delivery 2024 to 2034
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
FIG. 01: Global Market Value (US$ Mn), 2018 to 2023
FIG. 02: Global Market Value (US$ Mn) Forecast, 2024 to 2034
FIG. 03: Global Market Value (US$ Mn) and Y-o-Y, 2024 to 2034
FIG. 04: Global Beta Lactams Segment Market Value (US$ Mn) By Region, 2018 to 2023
FIG. 05: Global Beta Lactams Segment Market Value (US$ Mn) By Region, 2024 to 2034
FIG. 06: Global Beta Lactams Segment Y-o-Y Growth Rate, By Region, 2024 to 2034
FIG. 07: Global Macrolides Segment Market Value (US$ Mn) By Region, 2018 to 2023
FIG. 08: Global Macrolides Segment Market Value (US$ Mn) By Region, 2024 to 2034
FIG. 09: Global Macrolides Segment Y-o-Y Growth Rate, By Region, 2024 to 2034
FIG. 10: Global Cephalosporins Segment Market Value (US$ Mn) By Region, 2018 to 2023
FIG. 11: Global Cephalosporins Segment Market Value (US$ Mn) By Region, 2024 to 2034
FIG. 12: Global Cephalosporins Segment Y-o-Y Growth Rate, By Region, 2024 to 2034
FIG. 13: Global Fluoroquinolones Segment Market Value (US$ Mn) By Region, 2018 to 2023
FIG. 14: Global Fluoroquinolones Segment Market Value (US$ Mn) By Region, 2024 to 2034
FIG. 15: Global Fluoroquinolones Segment Y-o-Y Growth Rate, By Region, 2024 to 2034
FIG. 16: Global Tetracycline Segment Market Value (US$ Mn) By Region, 2018 to 2023
FIG. 17: Global Tetracycline Segment Market Value (US$ Mn) By Region, 2024 to 2034
FIG. 18: Global Tetracycline Segment Y-o-Y Growth Rate, By Region, 2024 to 2034
FIG. 19: Global Other Products Segment Market Value (US$ Mn) By Region, 2018 to 2023
FIG. 20: Global Other Products Segment Market Value (US$ Mn) By Region, 2024 to 2034
FIG. 21: Global Other Products Segment Y-o-Y Growth Rate, By Region, 2024 to 2034
FIG. 22: Global Hospital Pharmacies Segment Market Value (US$ Mn) By Region, 2018 to 2023
FIG. 23: Global Hospital Pharmacies Segment Market Value (US$ Mn) By Region, 2024 to 2034
FIG. 24: Global Hospital Pharmacies Segment Y-o-Y Growth Rate, By Region, 2024 to 2034
FIG. 25: Global Retail Pharmacies and Drug Stores Segment Market Value (US$ Mn) By Region, 2018 to 2023
FIG. 26: Global Retail Pharmacies and Drug Stores Segment Market Value (US$ Mn) By Region, 2024 to 2034
FIG. 27: Global Retail Pharmacies and Drug Stores Segment Y-o-Y Growth Rate, By Region, 2024 to 2034
FIG. 28: Global Online Pharmacies Segment Market Value (US$ Mn) By Region, 2018 to 2023
FIG. 29: Global Online Pharmacies Segment Market Value (US$ Mn) By Region, 2024 to 2034
FIG. 30: Global Online Pharmacies Segment Y-o-Y Growth Rate, By Region, 2024 to 2034
FIG. 31: Global Oral Segment Market Value (US$ Mn) By Region, 2018 to 2023
FIG. 32: Global Oral Segment Market Value (US$ Mn) By Region, 2024 to 2034
FIG. 33: Global Oral Segment Y-o-Y Growth Rate, By Region, 2024 to 2034
FIG. 34: Global Intravenous Segment Market Value (US$ Mn) By Region, 2018 to 2023
FIG. 35: Global Intravenous Segment Market Value (US$ Mn) By Region, 2024 to 2034
FIG. 36: Global Intravenous Segment Y-o-Y Growth Rate, By Region, 2024 to 2034
FIG. 37: Global Intramuscular Segment Market Value (US$ Mn) By Region, 2018 to 2023
FIG. 38: Global Intramuscular Segment Market Value (US$ Mn) By Region, 2024 to 2034
FIG. 39: Global Intramuscular Segment Y-o-Y Growth Rate, By Region, 2024 to 2034
FIG. 40: Global Other Mode of Delivery Segment Market Value (US$ Mn) By Region, 2018 to 2023
FIG. 41: Global Other Mode of Delivery Segment Market Value (US$ Mn) By Region, 2024 to 2034
FIG. 42: Global Other Mode of Delivery Segment Y-o-Y Growth Rate, By Region, 2024 to 2034
FIG. 43: North America Market Value (US$ Mn), By Country 2018 to 2023
FIG. 44: North America Market Value (US$ Mn), By Country 2024 to 2034
FIG. 45: North America Market Value (US$ Mn), By Drug Class 2018 to 2023
FIG. 46: North America Market Value (US$ Mn), By Drug Class 2024 to 2034
FIG. 47: North America Market Value (US$ Mn), By Distribution Channel 2018 to 2023
FIG. 48: North America Market Value (US$ Mn), By Distribution Channel 2024 to 2034
FIG. 49: North America Market Value (US$ Mn), By Mode of Delivery 2018 to 2023
FIG. 50: North America Market Value (US$ Mn), By Mode of Delivery 2024 to 2034
FIG. 51: Latin America Market Value (US$ Mn), By Country 2018 to 2023
FIG. 52: Latin America Market Value (US$ Mn), By Country 2024 to 2034
FIG. 53: Latin America Market Value (US$ Mn), By Drug Class 2018 to 2023
FIG. 54: Latin America Market Value (US$ Mn), By Drug Class 2024 to 2034
FIG. 55: Latin America Market Value (US$ Mn), By Distribution Channel 2018 to 2023
FIG. 56: Latin America Market Value (US$ Mn), By Distribution Channel 2024 to 2034
FIG. 57: Latin America Market Value (US$ Mn), By Mode of Delivery 2018 to 2023
FIG. 58: Latin America Market Value (US$ Mn), By Mode of Delivery 2024 to 2034
FIG. 59: Europe Market Value (US$ Mn), By Country 2018 to 2023
FIG. 60: Europe Market Value (US$ Mn), By Country 2024 to 2034
FIG. 61: Europe Market Value (US$ Mn), By Drug Class 2018 to 2023
FIG. 62: Europe Market Value (US$ Mn), By Drug Class 2024 to 2034
FIG. 63: Europe Market Value (US$ Mn), By Distribution Channel 2018 to 2023
FIG. 64: Europe Market Value (US$ Mn), By Distribution Channel 2024 to 2034
FIG. 65: Europe Market Value (US$ Mn), By Mode of Delivery 2018 to 2023
FIG. 66: Europe Market Value (US$ Mn), By Mode of Delivery 2024 to 2034
FIG. 67: Japan Market Value (US$ Mn), By Country 2018 to 2023
FIG. 68: Japan Market Value (US$ Mn), By Country 2024 to 2034
FIG. 69: Japan Market Value (US$ Mn), By Drug Class 2018 to 2023
FIG. 70: Japan Market Value (US$ Mn), By Drug Class 2024 to 2034
FIG. 71: Japan Market Value (US$ Mn), By Mode of Delivery 2018 to 2023
FIG. 72: Japan Market Value (US$ Mn), By Distribution Channel 2024 to 2034
FIG. 73: Japan Market Value (US$ Mn), By Mode of Delivery 2018 to 2023
FIG. 74: Japan Market Value (US$ Mn), By Mode of Delivery 2024 to 2034
FIG. 75: APEJ Market Value (US$ Mn), By Country 2018 to 2023
FIG. 76: APEJ Market Value (US$ Mn), By Country 2024 to 2034
FIG. 77: APEJ Market Value (US$ Mn), By Drug Class 2018 to 2023
FIG. 78: APEJ Market Value (US$ Mn), By Drug Class 2024 to 2034
FIG. 79: APEJ Market Value (US$ Mn), By Distribution Channel 2018 to 2023
FIG. 80: APEJ Market Value (US$ Mn), By Distribution Channel 2024 to 2034
FIG. 81: APEJ Market Value (US$ Mn), By Mode of Delivery 2018 to 2023
FIG. 82: APEJ Market Value (US$ Mn), By Mode of Delivery 2024 to 2034
FIG. 83: MEA Market Value (US$ Mn), By Country 2018 to 2023
FIG. 84: MEA Market Value (US$ Mn), By Country 2024 to 2034
FIG. 85: MEA Market Value (US$ Mn), By Drug Class 2018 to 2023
FIG. 86: MEA Market Value (US$ Mn), By Drug Class 2024 to 2034
FIG. 87: MEA Market Value (US$ Mn), By Distribution Channel 2018 to 2023
FIG. 88: MEA Market Value (US$ Mn), By Distribution Channel 2024 to 2034
FIG. 89: MEA Market Value (US$ Mn), By Mode of Delivery 2018 to 2023
FIG. 90: MEA Market Value (US$ Mn), By Mode of Delivery 2024 to 2034
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the value of the pharyngitis market in 2024?
The global pharyngitis market is calculated at US$ 1.45 billion in 2024.
How big is the size of the global market expected to be by 2034?
Worldwide demand for pharyngitis treatment products is projected to reach a valuation of US$ 2.08 billion by 2034.
At what rate is the demand for pharyngitis treatment products projected to increase?
The market for pharyngitis is projected to expand at a CAGR of 3.7% from 2024 to 2034.
What is the expected contribution of North America to global market revenue?
North America is approximated to account for 35.9% share of global market revenue by 2034.
What is the market scenario for the oral delivery mode?
Revenue from oral pharyngitis treatment products is evaluated to reach US$ 879.7 million by 2034.
At what CAGR is the demand for pharyngitis treatment products estimated to increase in South Korea?
Sales of pharyngitis treatment products in South Korea are forecasted to rise at a CAGR of 4.4% from 2024 to 2034.
Pharyngitis Market